GLP-1 (7-36) amide
Also known as: Active GLP-1, GLP-1, GLP-1 amide, GLP-1(7-36)NH2, Glucagon-like peptide-1, Glucagon-like peptide-1 (7-36) amide, Proglucagon 78-107 amide
Source GLP-1 (7-36) amide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
GLP‑1 (7‑36) amide is the physiologic active form of glucagon‑like peptide‑1, a 30‑amino‑acid hormone that regulates glucose homeostasis and appetite.
Mechanism of Action
Agonist of the GLP-1 receptor, enhancing glucose‑dependent insulin secretion and suppressing glucagon release.
Routes of Administration
Goals & Uses
- NeuroprotectionNeurologyLow
- Glycemic control (type 2 diabetes)Metabolic / EndocrineHigh
- Cardiovascular risk reductionCardiovascularModerate
- CardioprotectionCardiovascularModerate
- Weight reductionMetabolicModerate
- Glycemic control in type 2 diabetesMetabolicHigh
- Body weight reduction / appetite suppressionMetabolic / ObesityModerate
- Beta-cell preservationMetabolicModerate
Contraindications
- Personal or family history of medullary thyroid carcinomaOncologicHigh
- Severe hypersensitivity to GLP-1 peptidesImmunologicalHigh
- Multiple endocrine neoplasia syndrome type 2 (MEN2)OncologicHigh
- Multiple endocrine neoplasia type 2OncologyHigh
- Medullary thyroid carcinomaOncologyHigh
Adverse Effects
- PancreatitisGastrointestinalRareInflammation of the pancreas
- HypoglycemiaMetabolicUncommonAbnormally low blood glucose
- Injection site reactionsLocalUncommon
- TachycardiaCardiovascularUncommonAbnormally fast heart rate
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
Drug Interactions
- InsulinModerateMay increase risk of low blood sugar
- Insulin and insulin secretagoguesModerate
- Oral medications with narrow therapeutic indexLow
- SulfonylureasModerateMay increase risk of low blood sugar
- DPP-4 inhibitors (e.g., sitagliptin)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Personal or family history of pancreatitisGastrointestinalRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric populationAgeRelative
- PediatricsAgeRelative
Regulatory Status
- European UnionInvestigationalSame as US.
- United StatesInvestigationalNot an approved drug; used as research peptide.
- United KingdomUnapprovedNot approved by MHRA. Research use only; GLP-1 analogs are approved through EMA/MHRA pathways.
The native peptide is not approved as a drug product in any major jurisdiction. It serves as the pharmacological reference compound and is used in academic and clinical research settings. Approved GLP-1 receptor agonist drugs are structurally modified analogs designed to resist DPP-4 degradation.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is GLP-1 (7-36) amide?
GLP‑1 (7‑36) amide is the physiologic active form of glucagon‑like peptide‑1, a 30‑amino‑acid hormone that regulates glucose homeostasis and appetite.
What is GLP-1 (7-36) amide used for?
GLP-1 (7-36) amide is educationally associated with: Neuroprotection, Glycemic control (type 2 diabetes), Cardiovascular risk reduction, Cardioprotection, Weight reduction, Glycemic control in type 2 diabetes, Body weight reduction / appetite suppression, Beta-cell preservation. Educational only — not medical advice.
How is GLP-1 (7-36) amide administered?
Recorded routes of administration: Intranasal, Intravenous, Subcutaneous.
What are the potential side effects of GLP-1 (7-36) amide?
Reported adverse effects include: Pancreatitis, Hypoglycemia, Injection site reactions, Tachycardia, Nausea, Vomiting. This list is not exhaustive — consult a qualified clinician.
Who should avoid GLP-1 (7-36) amide?
Recorded contraindications: Personal or family history of medullary thyroid carcinoma, Severe hypersensitivity to GLP-1 peptides, Multiple endocrine neoplasia syndrome type 2 (MEN2), Multiple endocrine neoplasia type 2, Medullary thyroid carcinoma. Consult a qualified clinician before use.